FI117672B - Menetelmä substituoitujen sulfoksidien syntetisoimiseksi - Google Patents

Menetelmä substituoitujen sulfoksidien syntetisoimiseksi Download PDF

Info

Publication number
FI117672B
FI117672B FI970102A FI970102A FI117672B FI 117672 B FI117672 B FI 117672B FI 970102 A FI970102 A FI 970102A FI 970102 A FI970102 A FI 970102A FI 117672 B FI117672 B FI 117672B
Authority
FI
Finland
Prior art keywords
alkyl
eller
alkoxy
chiral
halogen
Prior art date
Application number
FI970102A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970102A (fi
FI970102A0 (fi
Inventor
Erik Magnus Larsson
Urban Jan Stenhede
Henrik Soerensen
Unge Per Oskar Sverker Von
Hanna Kristina Cotton
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI117672(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of FI970102A publication Critical patent/FI970102A/fi
Publication of FI970102A0 publication Critical patent/FI970102A0/fi
Application granted granted Critical
Publication of FI117672B publication Critical patent/FI117672B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI970102A 1994-07-15 1997-01-10 Menetelmä substituoitujen sulfoksidien syntetisoimiseksi FI117672B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9402510 1994-07-15
SE9402510A SE504459C2 (sv) 1994-07-15 1994-07-15 Förfarande för framställning av substituerade sulfoxider
SE9500818 1995-07-03
PCT/SE1995/000818 WO1996002535A1 (fr) 1994-07-15 1995-07-03 Procede de synthese de sulfoxydes substitues

Publications (3)

Publication Number Publication Date
FI970102A FI970102A (fi) 1997-01-10
FI970102A0 FI970102A0 (fi) 1997-01-10
FI117672B true FI117672B (fi) 2007-01-15

Family

ID=20394753

Family Applications (2)

Application Number Title Priority Date Filing Date
FI970102A FI117672B (fi) 1994-07-15 1997-01-10 Menetelmä substituoitujen sulfoksidien syntetisoimiseksi
FI970102D FI117830B (fi) 1994-07-15 1997-01-10 Menetelmä substituoitujen sulfoksidien syntetisoimiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI970102D FI117830B (fi) 1994-07-15 1997-01-10 Menetelmä substituoitujen sulfoksidien syntetisoimiseksi

Country Status (42)

Country Link
US (1) US5948789A (fr)
EP (1) EP0773940B2 (fr)
JP (1) JP3795917B2 (fr)
KR (1) KR100356252B1 (fr)
CN (1) CN1070489C (fr)
AR (1) AR003443A1 (fr)
AT (1) ATE242233T1 (fr)
AU (1) AU688074B2 (fr)
BR (1) BR9508292A (fr)
CA (1) CA2193994C (fr)
CZ (1) CZ297987B6 (fr)
DE (1) DE69530987T3 (fr)
DK (1) DK0773940T4 (fr)
DZ (1) DZ1911A1 (fr)
EE (1) EE03354B1 (fr)
EG (1) EG24534A (fr)
ES (1) ES2199998T5 (fr)
FI (2) FI117672B (fr)
HK (1) HK1008331A1 (fr)
HR (1) HRP950401B1 (fr)
HU (1) HU226361B1 (fr)
IL (1) IL114477A (fr)
IS (1) IS1772B (fr)
MA (1) MA23611A1 (fr)
MX (1) MX9700358A (fr)
MY (1) MY113180A (fr)
NO (1) NO312101B1 (fr)
NZ (1) NZ289959A (fr)
PL (1) PL186342B1 (fr)
PT (1) PT773940E (fr)
RU (1) RU2157806C2 (fr)
SA (1) SA95160294B1 (fr)
SE (1) SE504459C2 (fr)
SI (1) SI0773940T2 (fr)
SK (1) SK284059B6 (fr)
TN (1) TNSN95081A1 (fr)
TR (1) TR199500861A2 (fr)
TW (1) TW372971B (fr)
UA (1) UA47409C2 (fr)
WO (1) WO1996002535A1 (fr)
YU (1) YU49475B (fr)
ZA (1) ZA955724B (fr)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
BR9810508A (pt) 1997-07-03 2000-09-05 Du Pont Pharm Co Composto, composição farmacêutica e método de tratamento de uma desordem
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
EP1056456A4 (fr) * 1998-01-30 2006-10-25 Sepracor Inc Compositions et procedes d'utilisation du r-lansoprazole
WO1999055157A1 (fr) * 1998-04-30 1999-11-04 Sepracor Inc. Compositions a base de r-rabeprazole et procedes
AU3967399A (en) * 1998-04-30 1999-11-16 Sepracor, Inc. S-rabeprazole compositions and methods
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CN1087739C (zh) * 1998-12-28 2002-07-17 中国科学院成都有机化学研究所 光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60020967T2 (de) 1999-06-30 2006-05-04 Takeda Pharmaceutical Co. Ltd. Kristalle von lansoprazole
WO2001014366A1 (fr) * 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Procede de preparation de derives optiquement actifs de sulfoxyde
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
ES2273829T3 (es) * 2000-04-28 2007-05-16 Takeda Pharmaceutical Company Limited Procedimiento para producir derivado de sulfoxido opticamente activo.
KR20080067713A (ko) 2000-05-15 2008-07-21 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
KR100869677B1 (ko) 2000-05-15 2008-11-21 다케다 야쿠힌 고교 가부시키가이샤 결정의 제조방법
WO2002012225A1 (fr) 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
CN1254473C (zh) * 2000-12-01 2006-05-03 武田药品工业株式会社 (r)－或(s)－兰索拉唑的结晶方法
JP2004536049A (ja) * 2001-04-13 2004-12-02 アプシンターム・リミテッド・ライアビリティ・カンパニー スルフィンアミドおよびスルホキシドの製造方法
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
CA2474246C (fr) 2002-03-05 2010-06-29 Astrazeneca Ab Sels d'alkylammonium d'omeprazole et d'esomeprazole
WO2003089408A2 (fr) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Pyridinylmethyl-sulphinyl-benzimidazole substitue optiquement actif et sels
WO2004002982A2 (fr) * 2002-06-27 2004-01-08 Dr. Reddy's Laboratories Limited Procede de preparation de composes sulfoxyde optiquement purs ou optiquement enrichis, notamment de l'esomeprazole amorphe et ses sels
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP2596792A1 (fr) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Préparations solides stables
EP1556043A1 (fr) 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Forme amorphe de sels d'esomeprazole
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
PT1578742E (pt) 2002-12-06 2013-01-24 Nycomed Gmbh Processo para preparar compostos activos opticamente puros
DK1575941T3 (da) * 2002-12-06 2012-07-09 Nycomed Gmbh Fremgangsmåde til fremstilling af (S)-pantoprazol
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
AU2003288576A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited Rabeprazole calcium
JP2006514108A (ja) 2002-12-19 2006-04-27 テバ ファーマシューティカル インダストリーズ リミティド パントプラゾールナトリウムの固体状態、それらの調製方法、及び公知のパントプラゾールナトリウム水和物の調製方法
WO2004060263A2 (fr) * 2003-01-07 2004-07-22 Ranbaxy Laboratories Limited Sels de magnesium de derives de l'imidazole
CA2517005A1 (fr) * 2003-02-20 2004-09-02 Santarus, Inc. Liberation immediate d'un complexe antacide d'omeprazole presentant une nouvelle formulation pour une elimination rapide et prolongee d'acide gastrique
MXPA05009183A (es) * 2003-02-28 2005-10-20 Ranbaxy Lab Ltd Polimorfos de s-omeprazol.
US20040235904A1 (en) * 2003-03-12 2004-11-25 Nina Finkelstein Crystalline and amorphous solids of pantoprazole and processes for their preparation
JP4355703B2 (ja) * 2003-03-13 2009-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 歯ぎしりの予防剤または治療剤
CA2520157A1 (fr) * 2003-03-28 2004-10-14 Sidem Pharma Procede de preparation enantioselective de derives de sulfoxydes
FR2852956B1 (fr) * 2003-03-28 2006-08-04 Negma Gild Procede de preparation enantioselective de derives de sulfoxydes
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US7683177B2 (en) 2003-06-10 2010-03-23 Teva Pharmaceutical Industries Ltd Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
WO2005054228A1 (fr) * 2003-12-05 2005-06-16 Hetero Drugs Limited Procede de preparation d'enantiomeres de pyridinylmethylsulfinyl- benzamide substitues
SE0400410D0 (sv) * 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
ES2327926T3 (es) 2004-04-28 2009-11-05 Hetero Drugs Limited Procedimiento de preparacion de compuestos de piridinilmetil-1h-benzimidazol en forma de enantiomeros simples o enantiomericamente enriquecidos.
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE602004025386D1 (de) * 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
MXPA06013623A (es) * 2004-06-02 2007-02-28 Altana Pharma Ag Procedimiento para la preparacion de compuestos piridin-2-ilmetilsulfinil-1h-benzimidazol.
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
AU2005257709C1 (en) 2004-06-24 2011-02-24 Astrazeneca Ab New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
WO2006001755A1 (fr) * 2004-06-24 2006-01-05 Astrazeneca Ab Nouvelle forme modifiee de cristaux de sels d'esomeprazole sodium
FR2876101B1 (fr) * 2004-10-05 2007-03-02 Sidem Pharma Sa Sa Procede de preparation enantioselective de derives de sulfoxydes
EP1802584B1 (fr) * 2004-10-11 2009-09-16 Ranbaxy Laboratories Limited Procedes de preparation de sulfoxydes substitues
US7592111B2 (en) * 2004-11-05 2009-09-22 Xerox Corporation Imaging member
CN101098867B (zh) * 2005-03-25 2010-08-11 丽珠医药集团股份有限公司 取代的亚砜类化合物和其制备方法及用途
ATE528301T1 (de) * 2005-03-25 2011-10-15 Livzon Pharmaceutical Group Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
WO2006120520A1 (fr) * 2005-05-06 2006-11-16 Glenmark Pharmaceuticals Limited Sel de strontium d'esomeprazole, procede de preparation de ce sel et compositions pharmaceutiques le contenant
US8247566B2 (en) * 2005-06-08 2012-08-21 Lek Pharmaceuticals D.D. Crystalline solvate of omeprazole sodium
US20070043085A1 (en) * 2005-08-19 2007-02-22 Glenmark Pharmaceuticals Limited Process for the preparation of amorphous form of neutral esomeprazole
CA2631919A1 (fr) 2005-12-05 2007-06-14 Astrazeneca Ab Nouveau procede de fabrication d'esomeprazole sous forme non saline
DE102005061720B3 (de) * 2005-12-22 2006-10-19 Ratiopharm Gmbh Enantioselektive Herstellung von Benzimidazolderivaten und ihren Salzen
EP1801110A1 (fr) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Sel d'arginine d'ésoméprazole
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
ATE428707T1 (de) 2005-12-28 2009-05-15 Union Quimico Farma Verfahren zur herstellung des (s)-enantiomers von omeprazol
CN1810803B (zh) * 2006-02-17 2010-11-17 中国科学院上海有机化学研究所 高对映体选择性制备(s)-奥美拉唑的方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) * 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US7786309B2 (en) * 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
BRPI0621832A2 (pt) 2006-07-05 2013-03-19 Lupin Ltd processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido
WO2008018091A1 (fr) * 2006-08-08 2008-02-14 Jubilant Organosys Limited Procédé de production de composés de sulfoxyde
JP2009196894A (ja) * 2006-10-13 2009-09-03 Eisai R & D Management Co Ltd スルフィニルベンズイミダゾール化合物またはその塩の製造方法
WO2008047681A1 (fr) 2006-10-13 2008-04-24 Eisai R & D Management Co., Ltd. Benzimidazole présentant une activité inhibitrice de la sécrétion d'acide gastrique
EP1947099A1 (fr) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Procédé pour l'élimination de solvant des sels d'oméprazole
ES2532854T3 (es) 2007-02-21 2015-04-01 Cipla Limited Proceso para la preparación de esomeprazol magnésico dihidrato
WO2008149204A1 (fr) * 2007-06-07 2008-12-11 Aurobindo Pharma Limited Procédé amélioré pour préparer un inhibiteur de la pompe à protons optiquement actif
CN101323609B (zh) * 2007-06-15 2013-05-01 成都福瑞生物工程有限公司 不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
WO2009066321A2 (fr) * 2007-10-03 2009-05-28 Ipca Laboratories Limited Procédé pour composés de sulfoxyde optiquement actifs
WO2009047775A2 (fr) 2007-10-08 2009-04-16 Hetero Drugs Limited Polymorphes de sels de l'ésoméprazole
AU2008310735B2 (en) 2007-10-12 2013-09-12 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal disorders independent of the intake of food
FR2925899B1 (fr) * 2007-12-27 2012-12-21 Sidem Pharma Sa Procede de preparation enantioselective de sulfoxydes.
CN101492459B (zh) * 2008-01-25 2011-04-27 山东轩竹医药科技有限公司 含烷氧乙酰基二氢异噁唑并吡啶化合物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
PE20091680A1 (es) 2008-03-10 2009-11-16 Takeda Pharmaceutical Cristal de compuestos de bencimidazol
CA2717578A1 (fr) * 2008-03-18 2009-09-24 Dr. Reddy's Laboratories Ltd. Procede de preparation du dexlansoprazole et autres formes polymorphes
CN101538264A (zh) * 2008-03-19 2009-09-23 中国科学院成都有机化学有限公司 手性亚砜类化合物的制备新方法
WO2009145368A1 (fr) * 2008-05-27 2009-12-03 Sk Chemicals Co., Ltd. Procédé amélioré de préparation de (s)-oméprazole à partir d'un racémate d'oméprazole à l’aide d'un agent de résolution optique
EP2143722A1 (fr) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Procédé de préparation de sodium ésoméprazole de haute pureté chimique et nouvelles formes de sodium ésoméprazole
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
EP2264024A1 (fr) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Procédé de préparation d'inhibiteurs de la pompe à protons énantiomériquement enrichis
IT1391776B1 (it) 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
CZ200990A3 (cs) * 2009-02-16 2010-08-25 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010097583A1 (fr) 2009-02-24 2010-09-02 Cipla Limited Polymorphe de l'ésoméprazole de potassium et sa préparation
CZ2009172A3 (cs) * 2009-03-17 2010-09-29 Zentiva, K.S. Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
US20130030186A1 (en) * 2009-06-02 2013-01-31 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
IT1395118B1 (it) 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
CA2788147A1 (fr) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Procede pour la preparation de formes cristallines de dexlansoprazole
US8912337B2 (en) 2010-06-24 2014-12-16 Cipla Limited Salts and polymorphs of dexrabeprazole
CN101914090B (zh) * 2010-08-13 2013-03-20 埃斯特维华义制药有限公司 左旋奥美拉唑的制备方法
CN102558150B (zh) * 2010-12-31 2014-03-12 正大天晴药业集团股份有限公司 取代亚砜化合物的合成方法
CN102321071B (zh) * 2011-07-20 2013-01-23 江苏奥赛康药业股份有限公司 一种高纯度埃索美拉唑钠的工业化生产方法
CN102977076A (zh) * 2011-09-02 2013-03-20 扬子江药业集团上海海尼药业有限公司 一种右兰索拉唑的制备方法
CN102329302A (zh) * 2011-10-22 2012-01-25 刘强 一种埃索美拉唑及其盐的制备方法
CN102408412A (zh) * 2011-10-25 2012-04-11 广东华南药业集团有限公司 高对映体选择性制备（s）- 奥美拉唑的方法
CN102432412A (zh) * 2011-10-28 2012-05-02 成都欣捷高新技术开发有限公司 一种手性亚砜类质子泵抑制剂或其可药用盐的制备方法
KR101300950B1 (ko) * 2011-10-31 2013-08-27 르노삼성자동차 주식회사 전기자동차의 공기 흡입 장치
WO2013140120A1 (fr) 2012-03-22 2013-09-26 Cipla Limited Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
CN102659763B (zh) * 2012-04-27 2014-01-22 南京优科生物医药研究有限公司 一种右旋兰索拉唑合成与纯化的方法
CN103044402B (zh) * 2012-12-31 2015-01-14 康普药业股份有限公司 埃索美拉唑钠合成生产方法
CN103113351B (zh) * 2013-03-08 2015-01-21 苏州特瑞药业有限公司 一种光学纯手性亚砜类化合物的制备方法
CN104177336A (zh) * 2013-05-28 2014-12-03 上海汇伦生命科技有限公司 一种对映选择性合成右兰索拉唑的方法
WO2015155307A1 (fr) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Combinaisons pharmaceutiques de rivaroxaban et d'inhibiteurs de pompe à protons
EP2933002A1 (fr) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques comprenants de dabigratan et des inhibiteurs de la pompe à protons
EP2980086B1 (fr) 2014-07-29 2016-06-15 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé efficace pour la préparation d'ésoméprazole (S)-binol complexe
KR20170098843A (ko) * 2014-12-26 2017-08-30 고쿠리츠다이가쿠호우진 도쿄다이가쿠 광학 활성의 프로톤 펌프 저해 화합물의 제조 방법
CN104610226A (zh) * 2014-12-31 2015-05-13 广东东阳光药业有限公司 一种右兰索拉唑的不对称氧化方法
ES2615637T3 (es) * 2015-03-06 2017-06-07 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento mejorado para la purificación óptica del esomeprazol
CN105218391B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 L‑酒石酸单酯单酰胺类化合物
CN105218392B (zh) * 2015-07-09 2017-11-21 天津青松华药医药有限公司 D‑酒石酸单酯单酰胺类化合物
CN105968097B (zh) * 2016-05-17 2019-05-03 杭州华东医药集团新药研究院有限公司 左旋泮托拉唑的工业化生产方法
CN106083818A (zh) * 2016-06-08 2016-11-09 扬子江药业集团有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106366070B (zh) * 2016-08-10 2019-06-11 上海万巷制药有限公司 一种高纯度埃索美拉唑钠的制备方法
CN106632248A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种左旋泮托拉唑钠的制备工艺
CN106632249A (zh) * 2016-09-30 2017-05-10 青岛云天生物技术有限公司 一种制备(s)‑泮托拉唑钠的方法
CN106866630B (zh) * 2017-04-01 2018-08-07 上海华源医药科技发展有限公司 一种右兰索拉唑的制备方法
CN110698482A (zh) * 2019-10-29 2020-01-17 株洲千金药业股份有限公司 一种s型手性亚砜类化合物的制备方法
CN110746428A (zh) * 2019-10-29 2020-02-04 株洲千金药业股份有限公司 一种r型手性亚砜类化合物的制备方法
CN113845510A (zh) * 2020-06-27 2021-12-28 鲁南制药集团股份有限公司 一种埃索美拉唑的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation

Also Published As

Publication number Publication date
IS1772B (is) 2001-06-01
YU47695A (sh) 1998-07-10
WO1996002535A1 (fr) 1996-02-01
PT773940E (pt) 2003-10-31
SI0773940T2 (sl) 2011-02-28
EG24534A (en) 2009-08-30
CN1070489C (zh) 2001-09-05
WO1996002535A8 (fr) 1999-12-23
SK4897A3 (en) 1997-08-06
JPH10504290A (ja) 1998-04-28
AU2994895A (en) 1996-02-16
CZ6497A3 (en) 1997-06-11
ATE242233T1 (de) 2003-06-15
HRP950401B1 (en) 2004-04-30
AU688074B2 (en) 1998-03-05
CN1157614A (zh) 1997-08-20
PL318165A1 (en) 1997-05-26
YU49475B (sh) 2006-05-25
UA47409C2 (uk) 2002-07-15
KR100356252B1 (ko) 2002-11-18
MX9700358A (es) 1997-04-30
IL114477A0 (en) 1995-11-27
HK1008331A1 (en) 1999-05-07
SE9402510L (sv) 1996-01-16
FI970102A (fi) 1997-01-10
SI0773940T1 (en) 2004-02-29
NZ289959A (en) 1998-01-26
DE69530987D1 (de) 2003-07-10
EP0773940B2 (fr) 2010-11-17
HU226361B1 (en) 2008-09-29
DE69530987T2 (de) 2004-05-19
IL114477A (en) 2001-07-24
FI970102A0 (fi) 1997-01-10
NO312101B1 (no) 2002-03-18
TNSN95081A1 (fr) 1996-02-06
EP0773940B1 (fr) 2003-06-04
AR003443A1 (es) 1998-08-05
EE03354B1 (et) 2001-02-15
KR970704731A (ko) 1997-09-06
HRP950401A2 (en) 1997-10-31
SK284059B6 (sk) 2004-09-08
HUT76642A (en) 1997-10-28
IS4406A (is) 1996-12-27
ES2199998T5 (es) 2011-03-16
DE69530987T3 (de) 2011-07-07
US5948789A (en) 1999-09-07
DK0773940T3 (da) 2003-09-15
FI117830B (fi) 2007-03-15
ZA955724B (en) 1996-01-15
DZ1911A1 (fr) 2002-02-17
TR199500861A2 (tr) 1996-06-21
BR9508292A (pt) 1997-12-23
PL186342B1 (pl) 2003-12-31
MA23611A1 (fr) 1996-04-01
ES2199998T3 (es) 2004-03-01
NO970153D0 (no) 1997-01-14
CZ297987B6 (cs) 2007-05-16
DK0773940T4 (da) 2011-02-07
JP3795917B2 (ja) 2006-07-12
RU2157806C2 (ru) 2000-10-20
TW372971B (en) 1999-11-01
SE9402510D0 (sv) 1994-07-15
NO970153L (no) 1997-01-14
MY113180A (en) 2001-12-31
SE504459C2 (sv) 1997-02-17
CA2193994C (fr) 2005-05-03
CA2193994A1 (fr) 1996-02-01
EP0773940A1 (fr) 1997-05-21
SA95160294B1 (ar) 2006-07-31

Similar Documents

Publication Publication Date Title
FI117672B (fi) Menetelmä substituoitujen sulfoksidien syntetisoimiseksi
EP0836601B1 (fr) Procede de purification optique pour derives de benzimidazole enrichis par enantiomorphe
KR101522865B1 (ko) 에소메프라졸 마그네슘 2수화물의 형태 a의 제조방법
WO2007140608A1 (fr) Procédé de préparation de l'ésoméprazole et de ses sels
CA2553877C (fr) Compose utile pour la synthese de s- et r-omeprazole et procede de preparation associe
EP1748998A1 (fr) Nouveau procede de synthese stereoselective de sulfoxydes de benzimidazole
CN114621188A (zh) 一种泮托拉唑的制备方法
MXPA98000160A (en) A process for the optic purification of derivatives of benzimidazol enriquecidos enantiomericame
KR20090041023A (ko) 2-(2-피리딜메틸)설피닐-1에이치-벤즈이미다졸의 제조방법
KR20020074984A (ko) 2-메틸클로라이드 피리딘 유도체 및 이를 이용한벤즈이미다졸 유도체의 제조방법
MXPA99007536A (en) Process for preparing eprosartan

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ASTRAZENECA AB

Free format text: ASTRAZENECA AB

FG Patent granted

Ref document number: 117830

Country of ref document: FI

Effective date: 20070315

FG Patent granted

Ref document number: 117830

Country of ref document: FI

MA Patent expired